8-[(2S,3R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-2,3-dihydrochromen-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one | 1414943-37-5

• 物质功能分类: 天然产物 - 黄酮类化合物
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 8-[(2S,3R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-2,3-dihydrochromen-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
• CAS: 1414943-37-5；16851-21-1
• 化学式: C₃₀H₂₀O₁₁
• 分子量: 556.5
• InChiKey: GFWPWSNIXRDQJC-LMSSTIIKSA-N

物化性质

• 熔点：
  244-245 °C (decomp)
• 沸点：
  922.7±65.0 °C(Predicted)
• 密度：
  1.681±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  41
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  194
• 氢给体数：
  7
• 氢受体数：
  11

文献信息

• Uses of morelloflavone
  申请人：Fujise Kenichi

  公开号：US20110217293A1

  公开（公告）日：2011-09-08

  Provided herein are methods of treating postangiplasty, in-stent restenosis or atherosclerosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone with or with a effective dose of one or more of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent. Also provided are pharmaceutical compositions comprising a morelloflavone or pharmaceutical combinations comprising a morelloflavone and one of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent.
• [EN] USES OF MORELLOFLAVONE<br/>[FR] UTILISATIONS DE LA MORELLOFLAVONE
  申请人：UNIV TEXAS

  公开号：WO2010014199A2

  公开（公告）日：2010-02-04

  Provided herein is a method of treating postangiplasty or instent restenosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone. Also provided is a method of treating postangiplasty or instent restenosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone and an HMG-CoA reductase inhibitor.